Treatment adherence in patients with headache: A systematic review

Headache

Volumn 54, Issue 5, 2014, Pages 795-816

  Ramsey, Rachelle R ^a,b   Ryan, Jamie L ^b   Hershey, Andrew D ^b,c   Powers, Scott W ^b   Aylward, Brandon S ^d,e   Hommel, Kevin A ^b,c  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SIBLEY HEART CENTER CARDIOLOGY   (United States)

Author keywords

adherence; headache; migraine; patient compliance; pediatric; self management

Indexed keywords

NON PRESCRIPTION DRUG;

ADULT; CHILD; FOLLOW UP; HEADACHE; HUMAN; JUVENILE; MEDLINE; METHODOLOGY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCINFO; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; TELECONSULTATION; BIBLIOGRAPHIC DATABASE; MEDICATION COMPLIANCE; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; HEADACHE; HUMANS; MEDICATION ADHERENCE; PATIENT COMPLIANCE;

EID: 84899952273     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12353     Document Type: Review

References (73)

1. Drotar D,. Promoting Adherence to Medical Treatment in Chronic Childhood Illness: Concepts, Methods, and Interventions. Mahwah: Lawrence Eribaum Associates; 2000.
2. Dunbar-Jacob J, Mortimer-Stephens MK,. Treatment adherence in chronic disease. J Clin Epidemiol. 2001; 54 (Suppl. 1): S57-S60.
3. Hommel KA, Davis CM, Baldassano RN,. Objective vs subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 589-593.
4. Rapoff MA,. Adherence to Pediatric Medical Regimens, 2nd edn. New York: Springer; 2010.
5. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS,. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43: 521-530.
6. Haynes RB,. Introduction. In:, Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979: 1-7.
7. Powers SW, Gilman DK, Hershey AD,. Suggestions for a biopsychosocial approach to treating children and adolescents who present with headache. Headache. 2006; 46 (Suppl. 3): S149-S150.
8. Powers SW, Andrasik F,. Biobehavioral treatment, disability, and psychological effects of pediatric headache. Pediatr Ann. 2005; 34: 461-465.
9. Kabbouche MA, Gilman DK,. Management of migraine in adolescents. Neuropsychiatr Dis Treat. 2008; 4: 535-548.
10. Rains JC, Lipchik GL, Penzien DB,. Behavioral facilitation of medical treatment for headache-part I: Review of headache treatment compliance. Headache. 2006; 46: 1387-1394.
11. Mulleners WM, Whitmarsh TE, Steiner TJ,. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia. 1998; 18: 52-56.
12. Packard RC, O'Connell P,. Medication compliance among headache patients. Headache. 1986; 26: 416-419.
13. Fitzpatrick RM, Hopkins AP,. Effects of referral to a specialist for headache. J R Soc Med. 1983; 76: 112-115.
14. Foley KA, Cady R, Martin V, et al. Treating early vs treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005; 45: 538-545.
15. Holroyd KA, Powers SW, Andrasik F,. Methodological issues in clinical trials of drug and behavior therapies. Headache. 2005; 45: 487-492.
16. Gallagher RM, Kunkel R,. Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache. 2003; 43: 36-43.
17. Spierings ELH, Miree LF,. Non-compliance with follow-up and improvement after treatment at a headache center. Headache. 1993; 33: 205-209.
18. Hoodin F, Brines BJ, Lake AE III, Wilson J, Saper JR,. Behavioral self-management in an inpatient headache treatment unit: Increasing adherence and relationship to changes in affective distress. Headache. 2000; 40: 377-383.
19. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. Ann Intern Med. 2009; 151: 264-269.
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health. 2008; 11: 44-47.
21. Katíc BJ, Rajagopalan S, Ho TW, Chen YT, Hu XH,. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011; 31: 488-500.
22. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK,. Predictors of adherence to triptans: Factors of sustained vs lapsed users. Headache. 2009; 49: 386-394.
23. Ifergane G, Wirguin I, Shvartzman P,. Triptans-why once? Headache. 2006; 46: 1261-1263.
24. Panconesi A, Pavone E, Franchini M, et al. Triptans: Low utilization and high turnover in the general population. Cephalalgia. 2010; 30: 576-581.
25. Etemad LR, Yang W, Globe D, Barlev A, Johnson KA,. Costs and utilization of triptan users who receive drug prophylaxis for migraine vs triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005; 11: 137-144.
26. Ferrari A, Stefani M, Sternieri S, Bertolotti M, Sternieri E,. Analgesic drug taking: Beliefs and behavior among headache patients. Headache. 1997; 37: 88-94.
27. Donnet A, Lanteri-Minet M, Aucoin F, Allaf B,. Use and overuse of antimigraine drugs by pharmacy personnel in France: COTA survey. Headache. 2009; 49: 1014-1021.
28. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
29. Linde M, Jonsson P, Hedenrud T,. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand. 2008; 118: 367-372.
30. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: Randomised controlled trial. BMJ. 2010; 341: c4871.
31. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC,. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia: an international journal of headache. May 2003; 23 (4): 293-301.
32. Rahimtoola H, Egberts AC, Buurma H, Tijssen CC, Leufkens HG,. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997. Cephalalgia: an international journal of headache. Jun 2001; 21 (5): 596-603.
33. Seok JI, Cho HI, Chung CS,. From transformed migraine to episodic migraine: Reversion factors. Headache. 2006; 46: 1186-1190.
34. Hedenrud T, Jonsson P, Linde M,. Beliefs about medicines and adherence among Swedish migraineurs. Ann Pharmacother. 2008; 42: 39-45.
35. Dozza AL, Krymchantowski AV,. Adherence to migraine treatment does not depend on the number of prescribed medications. Arq Neuropsiquiatr. 2013; 71: 171-173.
36. Krymchantowski A, Tavares C,. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Medgenmed. 2004; 6: 48. Available at: www.medscape.com/viewarticle/482361 (accessed March 14, 2014).
37. Heckman BD, Ellis G,. Preventive medication adherence in African American and Caucasian headache patients. Headache. 2011; 51: 520-532.
38. Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweifler RM,. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache. 2006; 46: 726-731.
39. Gaul C, van Doorn C, Webering N, et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: An observational study. J Headache Pain. 2011; 12: 475-483.
40. Lafata JE, Tunceli O, Cerghet M, Sharma KP, Lipton RB,. The use of migraine preventive medications among patients with and without migraine headaches. Cephalalgia. 2010; 30: 97-104.
41. Yaldo AZ, Wertz DA, Rupnow MF, Quimbo RM,. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Clin Ther. 2008; 30: 2452-2460.
42. Attar HS, Chandramani S,. Impact of physician empathy on migraine disability and migraineur compliance. Ann Indian Acad Neurol. 2012; 15 (Suppl. 1): S89-S94.
43. Ezra Y, Gotkine M, Goldman S, Adahan HM, Ben-Hur T,. Hypnotic relaxation vs amitriptyline for tension-type headache: Let the patient choose. Headache. 2012; 52: 785-791.
44. Ramsden CE, Mann JD, Faurot KR, et al. Low omega-6 vs low omega-6 plus high omega-3 dietary intervention for chronic daily headache: Protocol for a randomized clinical trial. Trials. 2011; 12: 97.
45. Heckman BD, Holroyd KA, O'Donnell FJ, et al. Race differences in adherence to headache treatment appointments in persons with headache disorders. J Natl Med Assoc. 2008; 100: 247-255.
46. Krymchantowski AV, Jevoux CC,. Topiramate vs divalproex sodium in the preventive treatment of migraine: A prospective "real-world" study. Headache. 2011; 51: 554-558.
47. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G,. Advice alone vs structured detoxification programmes for medication overuse headache: A prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006; 26: 1097-1105.
48. Lemstra M, Stewart B, Olszynski WP,. Effectiveness of multidisciplinary intervention in the treatment of migraine: A randomized clinical trial. Headache. 2002; 42: 845-854.
49. Nappi G, Jensen R, Nappi RE, Sances G, Torelli P, Olesen J,. Diaries and calendars for migraine. A review. Cephalalgia. 2006; 26: 905-916.
50. Cady R, Martin V, Adelman J, Diamond M, Sajjan S, Hu XH,. Migraine treatment with rizatriptan and non-triptan usual care medications: A pharmacy-based study. Headache. 2004; 44: 900-907.
51. Allena M, Cuzzoni MG, Tassorelli C, Nappi G, Antonaci F,. An electronic diary on a palm device for headache monitoring: A preliminary experience. J Headache Pain. 2012; 13: 537-541.
52. Tassorelli C, Sances G, Allena M, et al. The usefulness and applicability of a basic headache diary before first consultation: Results of a pilot study conducted in two centres. Cephalalgia. 2008; 28: 1023-1030.
53. Moloney MF, Aycock DM, Cotsonis GA, Myerburg S, Farino C, Lentz M,. An internet-based migraine headache diary: Issues in internet-based research. Headache. 2009; 49: 673-686.
54. Kleiboer A, Sorbi M, Merelle S, Passchier J, van Doornen L,. Utility and preliminary effects of online digital assistance (ODA) for behavioral attack prevention in migraine. Telemed J E Health. 2009; 15: 682-690.
55. Sorbi MJ, Mak SB, Houtveen JH, Kleiboer AM, van Doornen LJ,. Mobile web-based monitoring and coaching: Feasibility in chronic migraine. J Med Internet Res. 2007; 9: e38.
56. Hershey AD, Powers SW, Bentti AL, Degrauw TJ,. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000; 40: 539-549.
57. Grazzi L, Andrasik F, Usai S, D'Amico D, Bussone G,. Pharmacological behavioural treatment for children and adolescents with tension-type headache: Preliminary data. Neurol Sci. 2004; 25 (Suppl. 3): S270-S271.
58. Usai S, Grazzi L, Andrasik F, Bussone G,. An innovative approach for migraine prevention in young age: A preliminary study. Neurol Sci. 2010; 31 (Suppl. 1): S181-S183.
59. Usai S, Grazzi L, Bussone G,. Gingkolide B as migraine preventive treatment in young age: Results at 1-year follow-up. Neurol Sci. 2011; 32 (Suppl. 1): S197-S199.
60. Andrasik F, Grazzi L, Usai S, Bussone G,. Pharmacological treatment compared to behavioural treatment for juvenile tension-type headache: Results at two-year follow-up. Neurol Sci. 2007; 28 (Suppl. 2): S235-S238.
61. Allen KD, McKeen LR,. Home-based multicomponent treatment of pediatric migraine. Headache. 1991; 31: 467-472.
62. Engel JM,. Children's compliance with progressive relaxation procedures for improving headache control. OTJR (Thorofare N J). 1993; 13: 219-230.
63. Wisniewski JJ, Genshaft JL, Mulick JA, Coury DL, Hammer D,. Relaxation therapy and compliance in the treatment of adolescent headache. Headache. 1988; 28: 612-617.
64. Guibert MB, Firestone P, McGrath P, Goodman JT, Cunningham JS,. Compliance factors in the behavioural treatment of headache in children and adolescents. Can J Behav Sci. 1990; 22: 37-44.
65. Kabbouche MA, Powers SW, Vockell AL, et al. Outcome of a multidisciplinary approach to pediatric migraine at 1, 2, and 5 years. Headache. 2005; 45: 1298-1303.
66. Golden W, Evans JK, Hu H,. Migraine strikes study: Factors in patients' decision to treat early. J Headache Pain. 2009; 10: 93-99.
67. Farley J, Hines S, Musk A, Ferrus S, Tepper V,. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr. 2003; 33: 211-218.
68. Gerson AC, Furth SL, Neu AM, Fivush BA,. Assessing associations between medication adherence and potentially modifiable psychosocial variables in pediatric kidney transplant recipients and their families. Pediatr Transplant. 2004; 8: 543-550.
69. Burgess SW, Sly PD, Morawska A, Devadason SG,. Assessing adherence and factors associated with adherence in young children with asthma. Respirology. 2008; 13: 559-563.
70. Kahana S, Drotar D, Frazier T,. Meta-Analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. J Pediatr Psychol. 2008; 33: 590-611.
71. Peterson AM, Takiya L, Finley R,. Meta-Analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003; 60: 657-665.
72. Powers SW, Patton SR, Hommel KA, Hershey AD,. Quality of life in childhood migraines: Clinical impact and comparison to other chronic illnesses. Pediatrics. 2003; 112: 1-5.
73. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SMA, Picavet HSJ, Launer LJ,. The impact of migraine on quality of life in the general population: The GEM study. Neurology. 2000; 55: 624-629. September 12, 2000.